372118-01-9

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4,6-DICHLOROPYRIDAZINE-3-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, METHYL 4,6-DICHLOROPYRIDAZINE-3-CARBOXYLATE serves as an essential intermediate for the production of various agrochemicals, including pesticides and herbicides. Its incorporation into these products helps improve their effectiveness in controlling pests and weeds, thereby enhancing crop yields and quality.
Used in Organic Compounds Synthesis:
METHYL 4,6-DICHLOROPYRIDAZINE-3-CARBOXYLATE is utilized as a versatile building block in the synthesis of a wide range of organic compounds. Its reactivity and functional groups make it a valuable component in the creation of new molecules with diverse applications in various industries.
Used in Chemical Research:
As a member of the pyridazine family, METHYL 4,6-DICHLOROPYRIDAZINE-3-CARBOXYLATE is employed in chemical research to explore its properties, reactivity, and potential applications. Researchers use METHYL 4,6-DICHLOROPYRIDAZINE-3-CARBOXYLATE to investigate new reaction pathways, develop novel synthetic methods, and discover its potential uses in various fields.

InChI:InChI=1/C6H4Cl2N2O2/c1-12-6(11)5-3(7)2-4(8)9-10-5/h2H,1H3

Upstream product

• 83878-89-1 2-diazo-3-oxo-pentanedioic acid dimethyl ester 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 372118-00-8 4,6-dihydroxy-pyridazine-3-carboxylic acid methyl ester 

Downstream Products

• 1030382-76-3 3-chloro-7-hydroxy-5-methyl-5H-pyrrolo[3,2-c]pyridazine-6-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors

Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of cancers and autoimmune diseases such as asthma, rheumatoid arthritis, and systemic lupus erythematous. We report the structure-guided optimization of pyridazine amide spleen tyrosine kinase inhibitors. Early representatives of this scaffold were highly potent and selective but mutagenic in an Ames assay. An approach that led to the successful identification of nonmutagenic examples, as well as further optimization to compounds with reduced cardiovascular liabilities is described. Select pharmacokinetic and in vivo efficacy data are presented.

PYRIDAZINE AMIDE COMPOUNDS

The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Imidazol-1-ylmethyl pyridazine derivatives

The invention provides imidazol-1-ylmethyl pyridazine derivatives of the formula: 1 that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5, R6 and Ar are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

Cyclic compounds

1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.